Publication:
Anticancer use of nanoparticles as nucleic acid carriers

dc.contributor.coauthorGozuacik, D.
dc.contributor.coauthorAkkoc, Y.
dc.contributor.coauthorKosar, A.
dc.contributor.coauthorDogan-Ekici, A. Isin
dc.contributor.coauthorEkici, Sinan
dc.contributor.departmentDepartment of Chemistry
dc.contributor.kuauthorAcar, Havva Funda Yağcı
dc.contributor.kuprofileFaculty Member
dc.contributor.otherDepartment of Chemistry
dc.contributor.schoolcollegeinstituteCollege of Sciences
dc.contributor.yokid178902
dc.date.accessioned2024-11-10T00:01:38Z
dc.date.issued2014
dc.description.abstractAdvances in nanotechnology opened up new horizons in the field of cancer research. Nanoparticles made of various organic and inorganic materials and with different optical, magnetic and physical characteristics have the potential to revolutionize the way we diagnose, treat and follow-up cancers. Importantly, designs that might allow tumor-specific targeting and lesser side effects may be produced. Nanoparticles may be tailored to carry conventional chemotherapeutics or new generation organic drugs. Currently, most of the drugs that are commonly used, are small chemical molecules targeting disease-related enzymes. Recent progress in RNA interference technologies showed that, even proteins that are considered to be "undruggable" by small chemical molecules, might be targeted by small RNAs for the purpose of curing diseases, including cancer. In fact, small RNAs such as siRNAs, shRNAs and miRNAs can drastically change cellular levels of almost any given disease-associated protein or protein group, resulting in a therapeutic effect. Gene therapy attempts were failing mainly due to delivery viral vector-related side effects. Biocompatible, non-toxic and efficient nanoparticle carriers raise new hopes for the gene therapy of cancer. In this review article, we discuss new advances in nucleic acid and especially RNA carrier nanoparticles, and summarize recent progress about their use in cancer therapy.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.issue9
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipScientific and Technological Research Council of Turkey-1001 (TUBITAK-1001) [112T272]
dc.description.sponsorshipEuropean Molecular Biology Organization (EMBO)
dc.description.sponsorshipSabanci and Koc Universities
dc.description.sponsorshipEMBO-SDIG Award
dc.description.sponsorshipTUBITAKIncentive Award
dc.description.sponsorshipTurkish Academy of Sciences (TUBA) GEBIP Award
dc.description.sponsorshipL'OREAL Turkey National Fellowship for Women in Science
dc.description.sponsorshipTUBITAK-BIDEB Scholarship for Ph.D.studies This work was supported by Scientific and Technological Research Council of Turkey-1001 (TUBITAK-1001 Grant number: 112T272), European Molecular Biology Organization (EMBO), Sabanci and Koc Universities. D. Gozuacik is a recipient of EMBO-SDIG Award. A. Kosar received TUBITAKIncentive Award. D. Gozuacik and A. Kosar are recipients of Turkish Academy of Sciences (TUBA) GEBIP Award. H. F. Yagci-Acar is a recipient of L'OREAL Turkey National Fellowship for Women in Science. Y. Akkoc is supported by TUBITAK-BIDEB Scholarship for Ph.D. studies.
dc.description.volume10
dc.identifier.doi10.1166/jbn.2014.1935
dc.identifier.eissn1550-7041
dc.identifier.issn1550-7033
dc.identifier.quartileQ3
dc.identifier.scopus2-s2.0-84904886096
dc.identifier.urihttp://dx.doi.org/10.1166/jbn.2014.1935
dc.identifier.urihttps://hdl.handle.net/20.500.14288/15999
dc.identifier.wos339430600006
dc.keywordsCancer
dc.keywordsDrug
dc.keywordsChemotherapy
dc.keywordsNanomedicine
dc.keywordsNanoparticles
dc.keywordsRna Interference
dc.keywordsSirna
dc.keywordsShrna
dc.keywordsMicrorna
dc.keywordsNanocarriers
dc.keywordsTargeted therapy small-interfering RNA
dc.keywordsEfficient sirna delivery
dc.keywordsMesoporous silica nanoparticles
dc.keywordsOvercome drug-resistance
dc.keywordsGene silencing activity
dc.keywordsInhibits tumor-growth
dc.keywordsSmall activating RNA
dc.keywordsIn-vivo delivery
dc.keywordsSystemic delivery
dc.keywordsBreast-cancer
dc.languageEnglish
dc.publisherAmer Scientific Publishers
dc.sourceJournal of Biomedical Nanotechnology
dc.subjectNanoscience
dc.subjectNanotechnology
dc.subjectMaterials science, biomaterials
dc.titleAnticancer use of nanoparticles as nucleic acid carriers
dc.typeReview
dspace.entity.typePublication
local.contributor.authorid0000-0001-5601-8814
local.contributor.kuauthorAcar, Havva Funda Yağcı
relation.isOrgUnitOfPublication035d8150-86c9-4107-af16-a6f0a4d538eb
relation.isOrgUnitOfPublication.latestForDiscovery035d8150-86c9-4107-af16-a6f0a4d538eb

Files